Our foreign technical cooperation partners includ Kitasato Daiichi Sankyo Co., Ltd. , Japan's largest vaccine researcher and manufacturer (formerly known as Kitasato Institute) and Crucell N.V. (now acquired by Johnson & Johnson) of the Netherlands.
ADIMMUNE has collaborated with Kitasato Daiichi Sankyo for more than 50 years, and obtained technologies for the production of tetanus vaccines, Japanese encephalitis vaccines, influenza vaccines, and bird flu vaccines; adimmune and Crucell established strategic alliance to enbale Adimmune to establish its EU PIC/S GMP quality system, and to establish the vaccine production technology,Crucell also became a strategic investor in Adimmune.
ADIMMUNE is committed to building itself into a leading supplier of biologics in the Asia-Pacific region, providing professional filling and finishing services. In recent years, it has worked with Protein Sciences Corporation (a subsidiary of Sanofi) and successfully commercialized its recombinant protein tetravalent influenza vaccine in the United Statesand other markets. Adimmune has also joined hands with Shenzhen Techdow Pharm Co., Ltd. to produce its low-molecular enoxaparin sodium to the European market.
Adimmune has been a reliable supplier of human vaccines for Taiwan’s epidemic prevention, and continues to invest substantial R&D resources in the development of new vaccines/bilogic products, and in acquiring marketing authorizations in the international markets. It has completed a multinational Phase III clinical trial of its tetravalent influenza vaccines in the EU, begun the Phase III clinical trial of enterovirus 71 vaccine, and planned for the H7N9 bird flu vaccine Phase III clinical trial. Otherpipeline research and development projects include recombinant protein subunit vaccines and technology platform, cell culture Japanese encephalitis vaccine, dengue fever vaccine, among others.
The vaccine industry is an important part of a country’s health. Adimmune not only fulfills the needs of domestic epidemic prevention, but has also been actively expanding to the international markets. To date, it has supplied more than 30 million doses of influenza vaccines for Taiwan’s domestic injection, and has also begun the commercial supply of influenza vaccine for China, with good potential of increases in market demands. Adimmune’s tetravalent influenza vaccine is also expected to gain entrances to the European markets and the Southeast Asian markets in the near future. Looking forward, Adimmune’s vision is to contribute its accumulated technologies and experience for the benefit of all humankind, to develop high-quality, high-efficiency, non-polluting biomedical products, to improve the health and the quality of life of the ublic, and to become a leading bio-pharmaceutical company in the Asia-Pacific region and a leader in Taiwan’s biotech industry, while continue our growth in the global market